{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mild-to-moderate+COVID-19&page=2",
    "query": {
      "condition": "Mild-to-moderate COVID-19",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mild-to-moderate+COVID-19&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T22:30:45.555Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04419025",
      "title": "Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COVID",
        "Sars-CoV2",
        "SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere",
        "Oxidative Stress"
      ],
      "interventions": [
        {
          "name": "N-acetylcysteine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cambridge Health Alliance",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 165,
      "start_date": "2020-09-23",
      "completion_date": "2021-05-14",
      "has_results": false,
      "last_update_posted_date": "2021-05-28",
      "last_synced_at": "2026-07-23T22:30:45.555Z",
      "location_count": 4,
      "location_summary": "Cambridge, Massachusetts • Everett, Massachusetts • Somerville, Massachusetts",
      "locations": [
        {
          "city": "Cambridge",
          "state": "Massachusetts"
        },
        {
          "city": "Everett",
          "state": "Massachusetts"
        },
        {
          "city": "Somerville",
          "state": "Massachusetts"
        },
        {
          "city": "Somerville",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04419025"
    },
    {
      "nct_id": "NCT04414124",
      "title": "A Clinical Study to Assess the Natural History of COVID-19 and Effects of KB109 and Supportive Self-care in Outpatients With Mild-to-moderate COVID-19",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Mild-to-moderate COVID-19"
      ],
      "interventions": [
        {
          "name": "KB109 + Self Supportive Care (SSC)",
          "type": "OTHER"
        },
        {
          "name": "Self Supportive Care (SSC) Alone",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Kaleido Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 350,
      "start_date": "2020-08-02",
      "completion_date": "2021-02-02",
      "has_results": false,
      "last_update_posted_date": "2021-08-13",
      "last_synced_at": "2026-07-23T22:30:45.555Z",
      "location_count": 16,
      "location_summary": "Hot Springs, Arkansas • Riverside, California • San Diego, California + 12 more",
      "locations": [
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04414124"
    },
    {
      "nct_id": "NCT04399356",
      "title": "Niclosamide for Mild to Moderate COVID-19",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "Niclosamide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Telehealth monitoring",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Tufts Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 73,
      "start_date": "2020-10-01",
      "completion_date": "2021-08-19",
      "has_results": true,
      "last_update_posted_date": "2022-04-12",
      "last_synced_at": "2026-07-23T22:30:45.555Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04399356"
    },
    {
      "nct_id": "NCT04896606",
      "title": "SARS-CoV-2 CTLS for Mild to Moderate COVID-19 Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Covid19"
      ],
      "interventions": [
        {
          "name": "Standard of Care",
          "type": "OTHER"
        },
        {
          "name": "SARS-CoV2-CTLS",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "New York Medical College",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 50,
      "start_date": "2021-09-20",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-07-23T22:30:45.555Z",
      "location_count": 4,
      "location_summary": "Valhalla, New York • Columbus, Ohio • Philadelphia, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "Valhalla",
          "state": "New York"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04896606"
    },
    {
      "nct_id": "NCT04504734",
      "title": "Bucillamine in Treatment of Patients With COVID-19",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Covid19"
      ],
      "interventions": [
        {
          "name": "Bucillamine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Revive Therapeutics, Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 713,
      "start_date": "2020-11-27",
      "completion_date": "2023-06-12",
      "has_results": false,
      "last_update_posted_date": "2023-07-07",
      "last_synced_at": "2026-07-23T22:30:45.555Z",
      "location_count": 46,
      "location_summary": "Cullman, Alabama • Huntsville, Alabama • Phoenix, Arizona + 38 more",
      "locations": [
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04504734"
    },
    {
      "nct_id": "NCT04343651",
      "title": "Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Coronavirus Disease 2019"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Leronlimab (700mg)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "CytoDyn, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 86,
      "start_date": "2020-04-01",
      "completion_date": "2021-09-20",
      "has_results": true,
      "last_update_posted_date": "2023-01-04",
      "last_synced_at": "2026-07-23T22:30:45.555Z",
      "location_count": 12,
      "location_summary": "Los Angeles, California • Palm Springs, California • Rancho Mirage, California + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palm Springs",
          "state": "California"
        },
        {
          "city": "Rancho Mirage",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Gainesville",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04343651"
    },
    {
      "nct_id": "NCT04701658",
      "title": "A Real World Study of Bamlanivimab in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "Bamlanivimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 109,
      "start_date": "2021-02-01",
      "completion_date": "2021-06-22",
      "has_results": true,
      "last_update_posted_date": "2021-11-16",
      "last_synced_at": "2026-07-23T22:30:45.555Z",
      "location_count": 1,
      "location_summary": "Albuquerque, New Mexico",
      "locations": [
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04701658"
    },
    {
      "nct_id": "NCT04779879",
      "title": "Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Covid19"
      ],
      "interventions": [
        {
          "name": "Sotrovimab (Gen1)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sotrovimab (Gen2)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Vir Biotechnology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "69 Years",
        "sex": "ALL",
        "summary": "18 Years to 69 Years"
      },
      "enrollment_count": 354,
      "start_date": "2021-02-18",
      "completion_date": "2022-04-06",
      "has_results": true,
      "last_update_posted_date": "2023-05-03",
      "last_synced_at": "2026-07-23T22:30:45.555Z",
      "location_count": 18,
      "location_summary": "Anniston, Alabama • Bakersfield, California • Northridge, California + 12 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Northridge",
          "state": "California"
        },
        {
          "city": "Ft. Pierce",
          "state": "Florida"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04779879"
    },
    {
      "nct_id": "NCT04734873",
      "title": "CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Covid-19"
      ],
      "interventions": [
        {
          "name": "CPI-006 2 mg/kg + SOC",
          "type": "DRUG"
        },
        {
          "name": "CPI-006 1 mg/kg + SOC",
          "type": "DRUG"
        },
        {
          "name": "Placebo + SOC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Corvus Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2021-02-25",
      "completion_date": "2021-08-18",
      "has_results": true,
      "last_update_posted_date": "2022-09-21",
      "last_synced_at": "2026-07-23T22:30:45.555Z",
      "location_count": 13,
      "location_summary": "Chula Vista, California • El Centro, California • La Mesa, California + 10 more",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "El Centro",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04734873"
    },
    {
      "nct_id": "NCT04840459",
      "title": "Use of Monoclonal Antibodies for the Treatment of Mild to Moderate COVID-19 in Non-Hospitalized Setting",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Covid19"
      ],
      "interventions": [
        {
          "name": "BAMLANIVIMAB",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CASIRIVIMAB",
          "type": "BIOLOGICAL"
        },
        {
          "name": "IMDEVIMAB",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sohail Rao",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 1000,
      "start_date": "2020-11-20",
      "completion_date": "2023-01-31",
      "has_results": false,
      "last_update_posted_date": "2022-03-29",
      "last_synced_at": "2026-07-23T22:30:45.555Z",
      "location_count": 3,
      "location_summary": "Edinburg, Texas • Rio Grande City, Texas",
      "locations": [
        {
          "city": "Edinburg",
          "state": "Texas"
        },
        {
          "city": "Edinburg",
          "state": "Texas"
        },
        {
          "city": "Rio Grande City",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04840459"
    }
  ]
}